<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294058</url>
  </required_header>
  <id_info>
    <org_study_id>RPC01-301</org_study_id>
    <secondary_id>2014-002320-27</secondary_id>
    <nct_id>NCT02294058</nct_id>
  </id_info>
  <brief_title>Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)</brief_title>
  <acronym>SUNBEAM</acronym>
  <official_title>A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ozanimod is effective in the treatment of&#xD;
      relapsing multiple sclerosis (RMS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2014</start_date>
  <completion_date type="Actual">December 22, 2016</completion_date>
  <primary_completion_date type="Actual">December 22, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Annualized Relapse Rate (ARR) During the Treatment Period</measure>
    <time_frame>12 months</time_frame>
    <description>The relapse rate was based on confirmed relapses. A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for &gt; 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores.&#xD;
Relapse rate was calculated as the total number of relapses divided by the total number of days in the study * 365.25.&#xD;
ARR was adjusted for region (Eastern Europe vs rest of world), Baseline age, and Baseline number of gadolinium-enhancing lesions; the natural log transformation of time on study was included as an offset term.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Number of New or Enlarging Hyperintense T2-Weighted Brain Magnetic Resonance Imaging (MRI) Lesions Per Scan Over 12 Months</measure>
    <time_frame>12 month treatment period; MRI scans were assessed at Month 6 and Month 12</time_frame>
    <description>The number of new or enlarging hyperintense T2-weighted brain MRI lesions per scan was based on the cumulative number of new or enlarging T2 lesions since Baseline over treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Number of Gadolinium Enhancing (GdE) Brain MRI Lesions at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Disability Progression Confirmed After 3 Months</measure>
    <time_frame>From first dose to the end of the 12-month treatment period</time_frame>
    <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Disability Progression Confirmed After 6 Months</measure>
    <time_frame>From first dose to the end of the 12-month treatment period</time_frame>
    <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 6 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Gadolinium Enhancing Lesion-Free at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>MRI scans were analyzed by blinded centralized reading facility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were T2 Lesion-Free at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>MRI scans were analyzed by blinded centralized reading facility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Normalized Brain Volume at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Brain volume (a measure of brain atrophy) was analyzed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 12 in Multiple Sclerosis Functional Composite (MSFC) Score Including the Low-Contrast Letter Acuity (LCLA) Test</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The MSFC-LCLA is a battery including the following 4 individual scales:&#xD;
Timed 25-Foot Walk is an ambulation measure of walking 25 feet with time taken recorded in seconds&#xD;
9-Hole Peg Test (9HPT) is a quantitative measure of upper extremity (arm and hand) function&#xD;
Symbol Digit Modalities Test (SDMT) is a measure of executive cognitive function that assesses processing speed, flexibility, and calculation ability&#xD;
Low-Contrast Letter Acuity Test (LCLA) used a standardized set of charts to assess low contrast visual acuity, charts are scored according to the number of letters that are identified correctly&#xD;
Z-scores were calculated for for each component and averaged to create an overall composite score, using the study population as the reference population. A z-score represents the number of standard deviations a patient's test result is higher (z &gt; 0) or lower (z &lt; 0) than the average test result (z = 0) of the reference population. A positive change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Physical Health Composite Summary and Mental Health Composite Summary Scores</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>The MSQOL-54 is a multidimensional health-related QOL measure that combines both generic and MS-specific items into a single instrument. The instrument includes 12 subscales, two summary scores, and two single-item measures.&#xD;
The two summary scores - physical health and mental health - are derived from a weighted combination of scale scores.&#xD;
The physical health composite score includes Physical function, Health perceptions, Energy/fatigue, Role limitations - physical, Pain, Sexual function, Social function, and Health distress.&#xD;
The mental health composite score includes Health distress, Overall quality of life, Emotional well-being, Role limitations - emotional, and Cognitive function.&#xD;
Each composite summary score has a range from 0 to 100 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From the first dose of study drug until 28 days following the last dose of study drug; mean exposure to study drug was 13.5 months for interferon beta-1a and 13.6 months for each ozanimod group.</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP). An AE can be any unfavorable or unintended sign, including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. A serious AE (SAE) is any untoward medical occurrence or effect that results in death, is life-threatening, requires hospitalization or prolongation of existing inpatient hospitalization. The investigator assessed the severity of AEs as mild, moderate, or severe.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1346</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Interferon beta-1a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozanimod 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozanimod 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanimod</intervention_name>
    <description>Capsules for oral administration once a day</description>
    <arm_group_label>Ozanimod 0.5 mg</arm_group_label>
    <arm_group_label>Ozanimod 1 mg</arm_group_label>
    <other_name>RPC1063</other_name>
    <other_name>Zeposia®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>Administered by intramuscular injection once a week</description>
    <arm_group_label>Interferon beta-1a</arm_group_label>
    <other_name>Avonex®</other_name>
    <other_name>IFN β-1a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to ozanimod</intervention_name>
    <description>Matching placebo capsules administered orally once a day</description>
    <arm_group_label>Interferon beta-1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to interferon beta-1a</intervention_name>
    <description>Placebo intramuscular injection once a week</description>
    <arm_group_label>Ozanimod 0.5 mg</arm_group_label>
    <arm_group_label>Ozanimod 1 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria&#xD;
&#xD;
          -  EDSS score between 0 and 5.0 at baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Primary progressive multiple sclerosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Sheffiled, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xenosciences Inc</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Josephs Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Neuro Specialists PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network Inc</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple Sclerosis Center at UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Neurological Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates PA</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates of Ormond Beach</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research LLC</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies Inc</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskamp Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Georgia Sleep Disorder Center and Neurology Associates</name>
      <address>
        <city>Douglasville</city>
        <state>Georgia</state>
        <zip>30134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants In Neurology</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidAmerica Neuroscience Research Foundation</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates In Neurology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists of Monmouth County PA</name>
      <address>
        <city>West Long Branch</city>
        <state>New Jersey</state>
        <zip>07764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Medical Care Associates PLLC</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates PA</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neuroscience Associates Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Multiple Sclerosis Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Neurology MS Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhupesh Dihenia MD PA</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EvergreenHealth</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Polyclinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology of Neurosurgery Associates of Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurological Disorders</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grodno Clinical Regional Hospital</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk Municipal Clinical Hospital 5</name>
      <address>
        <city>Minsk</city>
        <zip>220026</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre of Neurology and Neurosurgery</name>
      <address>
        <city>Minsk</city>
        <zip>220114</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk City Clinical Hospital 9</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Diagnostic Centre</name>
      <address>
        <city>Vitebsk</city>
        <zip>210023</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Hospital</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Banja Luka</name>
      <address>
        <city>Banja Luka</city>
        <zip>51000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center University of Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Tuzla</name>
      <address>
        <city>Tuzla</city>
        <zip>75000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy HBAT</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv Naum EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment National Cardiology Hospital EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Aleksandrovska EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy - MHAT</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Sveta Marina EAD</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Neuro Outaouais</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J9J 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Varazdin</name>
      <address>
        <city>Varazdin</city>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Sestre Milosrdnice</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Sveti duh</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv Anny v Brne</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Neurological Practice Radomir Talab MD</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava prispevkova organizace</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna Fakultni Nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni as Nemocnice Teplice oz</name>
      <address>
        <city>Teplice</city>
        <zip>415 29</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>EE-51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aversi Clinic LTD</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD MediClubGeorgia</name>
      <address>
        <city>Tbilisi</city>
        <zip>¿0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarajishvili Institute of Neurology</name>
      <address>
        <city>Tbilisi</city>
        <zip>¿0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curatio JSC</name>
      <address>
        <city>Tbilisi</city>
        <zip>¿0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd DEKA</name>
      <address>
        <city>Tbilisi</city>
        <zip>¿0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Wilfried Luer</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13088</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachklinikum Teupitz</name>
      <address>
        <city>Brandenburg</city>
        <zip>15755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich Heine Universitat Dusseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DataMed GmbH</name>
      <address>
        <city>Köln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen gGmbH</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Philipps Universitat Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Krankenhaus Potsdam-Sanssouci GmbH</name>
      <address>
        <city>Potsdam</city>
        <zip>14471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brueder</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroPoint Akademie</name>
      <address>
        <city>Ulm</city>
        <zip>89079</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Gyula Korhaz es Rendelointezet</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Korhaz</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Latvian Maritime Medicine Centre</name>
      <address>
        <city>Riga</city>
        <zip>LV-1015</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital clinic Gailezers</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-5808</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSP Institutul de Medicina Urgenta</name>
      <address>
        <city>Chisinau</city>
        <zip>2004</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Hospital Sf Arhanghel Mihail</name>
      <address>
        <city>Chisinau</city>
        <zip>2005</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Neurologie si Neurochirurgie</name>
      <address>
        <city>Chisinau</city>
        <zip>2028</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>2001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B&amp;B Robert Bonek, Pawel Bochniak, Spolka Cywilna</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-795</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi</name>
      <address>
        <city>Czeladz</city>
        <zip>41-250</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copernicus Podmiot Leczniczy Sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akson Clinical Research Maciejowski Bielecki Sp. Jawna</name>
      <address>
        <city>Jaroslaw</city>
        <zip>37-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej NEURO-MEDIC</name>
      <address>
        <city>Katowice</city>
        <zip>40-555</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.A.- Lek A.M.Maciejowscy Spolka Cywilna</name>
      <address>
        <city>Katowice</city>
        <zip>40-595</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo-Med Zielinski i wsp. Sp.J.</name>
      <address>
        <city>Katowice</city>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEURO- CARE Site Management Organization Gabriela Klodowska-Duda</name>
      <address>
        <city>Katowice</city>
        <zip>40-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RESMEDICA Spolka z o.o.</name>
      <address>
        <city>Kielce</city>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zespol Leczniczo-Rehabilitacyjny Centrum Kompleksowej Rehabilitacji</name>
      <address>
        <city>Konstancin Jeziorna</city>
        <zip>05-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ NEUROMED M. I M. Nastaj Spolka Partnerska</name>
      <address>
        <city>Lublin</city>
        <zip>20-059</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Neurologii Krzysztof Selmaj</name>
      <address>
        <city>Lódzkie</city>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Mazowieckie</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska</name>
      <address>
        <city>Plewiska</city>
        <zip>62-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej KENDRON</name>
      <address>
        <city>Podlaskie</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska dr nmed Monika Lyczak</name>
      <address>
        <city>Pomorskie</city>
        <zip>80-299</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku</name>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Medyk</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski</name>
      <address>
        <city>Warminsko-mazurskie</city>
        <zip>10-443</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Warsaw</city>
        <zip>00-739</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne NeuroProtect</name>
      <address>
        <city>Warszawa</city>
        <zip>01-697</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne doktorA</name>
      <address>
        <city>Warszawa</city>
        <zip>05-077</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta</name>
      <address>
        <city>Almada</city>
        <zip>2805-267</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar E Universitario de Coimbra EPE</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Beatriz Angelo</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Neurologico Senior</name>
      <address>
        <city>Torres Vedras</city>
        <zip>2560-280</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colentina Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>20125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cluj Clinical County Hospital</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400012</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cai Ferate Clinical Hospital</name>
      <address>
        <city>Constanta</city>
        <zip>900123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibiu Emergency County Clinical Hospital</name>
      <address>
        <city>Sibiu</city>
        <zip>550166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timisoara Emergency County Clinical Hospital</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Hospital</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belgorod Regional Clinical Hospital</name>
      <address>
        <city>Belgorod</city>
        <zip>308007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryansk Regional Hospital 1</name>
      <address>
        <city>Bryansk</city>
        <zip>241033</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk City Clinical Hospital 3</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital 1</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Complex Vashe Zdorovie</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Clinical Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Khanty-mansiysk</city>
        <zip>628012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirov City Clinical Hospital 1</name>
      <address>
        <city>Kirov</city>
        <zip>610014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical Academy</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk Regional Clinical Hospital</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital 2 na NA Semashko OAO RZhD</name>
      <address>
        <city>Moscow</city>
        <zip>107150</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 24</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 1 na NIPirogov</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center of Neurology of RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 11</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhniy Novgorod City Hospital 33</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 3 Nizhniy Novgorod Geriatrics Centre</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siberian Regional Medical Center</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk State Medical University</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penza Regional Clinical Hospital na NN Burdenko</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm State Medical Academy</name>
      <address>
        <city>Perm</city>
        <zip>614045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Hospital na VA Baranov</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pyatigorsk City Hospital 2</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Regional Clinical Hospital</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Regional Clinical Hospital named after MI Kalinin</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical Academy</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital 31</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Nikolaevskaya Bolnitsa</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Multi Field City Hospital 2</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First St Petersburg State Medical University na IP Pavlov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Human Brain RAN</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 40</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siberian State Medical University</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Budget Institution of Healthcare Tver Regional Clinical Hospital</name>
      <address>
        <city>Tver</city>
        <zip>125170</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neftyanik Medical and Sanitary Unit</name>
      <address>
        <city>Tyumen</city>
        <zip>625000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuvatov Republican Clinical Hospital</name>
      <address>
        <city>Ufa</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Clinical Hospital 8</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centar Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona/ Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Moises Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Goteborg</city>
        <zip>SE-41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MI Cherkasy Regional Hospital of Cherkasy Regional Council</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 4 of Chernihiv City Council</name>
      <address>
        <city>Chernihiv</city>
        <zip>14001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Treatment and Preventive Institution Chernihiv Regional Clinical Hospital</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Chernivtsi Regional Psychiatric Hospital</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano Frankivsk City Clinical Hospital 1</name>
      <address>
        <city>Ivano Frankivsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital.</name>
      <address>
        <city>Ivano Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital Center for Emergency Medical Care and Disaster Medicine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution of Health Care Kharkiv Clinical City Hospital 7</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Center for Radiation Medicine, Institute of Clinical Radiology</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital 4</name>
      <address>
        <city>Kyiv</city>
        <zip>3110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Clinical Hospital</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal City Clinical Hospital 5</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Reconstructive and Rehabilitation Medicine University Clinic of ONMedU</name>
      <address>
        <city>Odesa</city>
        <zip>65009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Odesa Regional Clinical Hospital</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital na NV Sklifosovskyi</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Center of Neurosurgery and Neurology</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Vinnytsia Regional Psychoneurological Hospital na OI Yushchenko</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution City Clinical Hospital 2</name>
      <address>
        <city>Zaporizhya</city>
        <zip>6972</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution 6th City Clinical Hospital of Zaporizhzhia City Council</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Zaporizhzhia</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital na OFHerbachevskyi of Zhytomyr Regional Council</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Mexico</country>
    <country>Peru</country>
  </removed_countries>
  <reference>
    <citation>Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA; SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.</citation>
    <PMID>31492651</PMID>
  </reference>
  <results_reference>
    <citation>Cree B, et al. The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics. Presented at the 69th Annual American Academy of Neurology Meeting, April 22-28, 2017, Boston, MA. Abstract No. P6-344</citation>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <results_first_submitted>December 22, 2017</results_first_submitted>
  <results_first_submitted_qc>November 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2020</results_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>RMS</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
    <mesh_term>Ozanimod</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 152 sites in 20 countries in Eastern and Western Europe, the United States, and New Zealand. Between December 2014 and November 2015, 1656 participants were screened, of whom 1346 were eligible and enrolled.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned to one of three treatment groups in a 1:1:1 ratio. Randomization was stratified by Baseline Expanded Disability Status Scale (EDSS) score (≤ 3.5, &gt; 3.5) and country.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Interferon Beta-1a</title>
          <description>Participants received 30 µg interferon beta-1a (IFN β-1a) by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for at least 12 months.</description>
        </group>
        <group group_id="P2">
          <title>Ozanimod 0.5 mg</title>
          <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection (identical in appearance to Interferon) weekly until the last participant had been treated for at least 12 months.</description>
        </group>
        <group group_id="P3">
          <title>Ozanimod 1 mg</title>
          <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection (identical in appearance to Interferon) weekly until the last participant had been treated for at least 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="451"/>
                <participants group_id="P3" count="447"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="445"/>
                <participants group_id="P2" count="453"/>
                <participants group_id="P3" count="448"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="412"/>
                <participants group_id="P2" count="425"/>
                <participants group_id="P3" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITT) population consisted of all randomized participants who received at least 1 dose of study drug; participants were analyzed according to the treatment they were randomized to receive and not according to what they actually received, if different.</population>
      <group_list>
        <group group_id="B1">
          <title>Interferon Beta-1a</title>
          <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
        </group>
        <group group_id="B2">
          <title>Ozanimod 0.5 mg</title>
          <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
        </group>
        <group group_id="B3">
          <title>Ozanimod 1 mg</title>
          <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="448"/>
            <count group_id="B2" value="451"/>
            <count group_id="B3" value="447"/>
            <count group_id="B4" value="1346"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="9.11"/>
                    <measurement group_id="B2" value="36.0" spread="9.43"/>
                    <measurement group_id="B3" value="34.8" spread="9.24"/>
                    <measurement group_id="B4" value="35.6" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="311"/>
                    <measurement group_id="B3" value="283"/>
                    <measurement group_id="B4" value="894"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="447"/>
                    <measurement group_id="B2" value="447"/>
                    <measurement group_id="B3" value="446"/>
                    <measurement group_id="B4" value="1340"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <description>Eastern Europe includes Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Latvia, Lithuania, Moldova, Poland, Romania, Russia, Serbia, and Ukraine.&#xD;
Rest of world includes the United States, Germany, Portugal, Spain, Sweden, and New Zealand.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Rest of World</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="419"/>
                    <measurement group_id="B2" value="419"/>
                    <measurement group_id="B3" value="415"/>
                    <measurement group_id="B4" value="1253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale (EDSS)</title>
          <description>The EDSS is a scale for quantifying disability in MS. Eight functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored on a scale of 0 (no disability) to 5 or 6 (more severe disability). Ambulation is also scored. Based on scores in these 8 functional systems and gait, an overall score ranging from 0 (normal) to 10 (death due to MS) in 0.5 unit increments is assigned. Participants with EDSS scores of 0.0 to 4.5 are fully ambulatory; patients with EDSS scores of 5.0 to 9.5 have impaired ambulation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.62" spread="1.138"/>
                    <measurement group_id="B2" value="2.65" spread="1.135"/>
                    <measurement group_id="B3" value="2.61" spread="1.160"/>
                    <measurement group_id="B4" value="2.62" spread="1.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since MS Symptom Onset</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.88" spread="5.877"/>
                    <measurement group_id="B2" value="7.16" spread="6.255"/>
                    <measurement group_id="B3" value="6.85" spread="6.449"/>
                    <measurement group_id="B4" value="6.96" spread="6.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since MS Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.71" spread="4.361"/>
                    <measurement group_id="B2" value="3.70" spread="4.518"/>
                    <measurement group_id="B3" value="3.60" spread="4.193"/>
                    <measurement group_id="B4" value="3.67" spread="4.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at MS Symptom Onset</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="8.92"/>
                    <measurement group_id="B2" value="29.3" spread="9.25"/>
                    <measurement group_id="B3" value="28.4" spread="8.42"/>
                    <measurement group_id="B4" value="29.1" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at MS Diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="9.01"/>
                    <measurement group_id="B2" value="32.7" spread="9.49"/>
                    <measurement group_id="B3" value="31.6" spread="8.81"/>
                    <measurement group_id="B4" value="32.4" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Annualized Relapse Rate (ARR) During the Treatment Period</title>
        <description>The relapse rate was based on confirmed relapses. A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for &gt; 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores.&#xD;
Relapse rate was calculated as the total number of relapses divided by the total number of days in the study * 365.25.&#xD;
ARR was adjusted for region (Eastern Europe vs rest of world), Baseline age, and Baseline number of gadolinium-enhancing lesions; the natural log transformation of time on study was included as an offset term.</description>
        <time_frame>12 months</time_frame>
        <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Annualized Relapse Rate (ARR) During the Treatment Period</title>
          <description>The relapse rate was based on confirmed relapses. A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for &gt; 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores.&#xD;
Relapse rate was calculated as the total number of relapses divided by the total number of days in the study * 365.25.&#xD;
ARR was adjusted for region (Eastern Europe vs rest of world), Baseline age, and Baseline number of gadolinium-enhancing lesions; the natural log transformation of time on study was included as an offset term.</description>
          <population>The ITT population consisted of all randomized participants who received at least 1 dose of study medication.</population>
          <units>relapses/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.350" lower_limit="0.279" upper_limit="0.440"/>
                    <measurement group_id="O2" value="0.241" lower_limit="0.188" upper_limit="0.308"/>
                    <measurement group_id="O3" value="0.181" lower_limit="0.140" upper_limit="0.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for multiple comparisons, each of the 2 treatment comparisons was tested at the alpha = 0.025 level.</p_value_desc>
            <method>Poisson regression model</method>
            <method_desc>Adjusted for region, Baseline age, number of gadolinium enhancing (GdE) lesions and included the natural log transformation of time as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.518</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.405</ci_lower_limit>
            <ci_upper_limit>0.663</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>To account for multiple comparisons, each of the 2 treatment comparisons was tested at the alpha = 0.025 level.</p_value_desc>
            <method>Poisson Regression Model</method>
            <method_desc>Adjusted for region, Baseline age and the number of GdE lesions, and included the natural log transformation of time on study as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.688</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.547</ci_lower_limit>
            <ci_upper_limit>0.864</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Number of New or Enlarging Hyperintense T2-Weighted Brain Magnetic Resonance Imaging (MRI) Lesions Per Scan Over 12 Months</title>
        <description>The number of new or enlarging hyperintense T2-weighted brain MRI lesions per scan was based on the cumulative number of new or enlarging T2 lesions since Baseline over treatment period.</description>
        <time_frame>12 month treatment period; MRI scans were assessed at Month 6 and Month 12</time_frame>
        <population>ITT population; participants with non-missing MRI results.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Number of New or Enlarging Hyperintense T2-Weighted Brain Magnetic Resonance Imaging (MRI) Lesions Per Scan Over 12 Months</title>
          <description>The number of new or enlarging hyperintense T2-weighted brain MRI lesions per scan was based on the cumulative number of new or enlarging T2 lesions since Baseline over treatment period.</description>
          <population>ITT population; participants with non-missing MRI results.</population>
          <units>T2 lesions/scan</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.836" lower_limit="2.331" upper_limit="3.451"/>
                    <measurement group_id="O2" value="2.139" lower_limit="1.777" upper_limit="2.575"/>
                    <measurement group_id="O3" value="1.465" lower_limit="1.203" upper_limit="1.784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for multiple comparisons, each of the 2 treatment comparisons was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Negative Binomial Regression Model</method>
            <method_desc>Adjusted for region, Baseline age and GdE lesions; included the natural log transformation of available MRI scans over 12 months as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.517</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.427</ci_lower_limit>
            <ci_upper_limit>0.625</ci_upper_limit>
            <estimate_desc>Rate Ratio = Ozanimod / IFN β-1a</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0032</p_value>
            <p_value_desc>To account for multiple comparisons, each of the 2 treatment comparisons was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Negative binomial regression model</method>
            <method_desc>Adjusted for region, Baseline age and GdE lesions; included the natural log transformation of available MRI scans over 12 months as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.754</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.625</ci_lower_limit>
            <ci_upper_limit>0.910</ci_upper_limit>
            <estimate_desc>Rate Ratio = Ozanimod / IFN β-1a</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Number of Gadolinium Enhancing (GdE) Brain MRI Lesions at Month 12</title>
        <time_frame>Month 12</time_frame>
        <population>ITT population; participants with non-missing MRI results.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Number of Gadolinium Enhancing (GdE) Brain MRI Lesions at Month 12</title>
          <population>ITT population; participants with non-missing MRI results.</population>
          <units>lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.433" lower_limit="0.295" upper_limit="0.635"/>
                    <measurement group_id="O2" value="0.287" lower_limit="0.197" upper_limit="0.418"/>
                    <measurement group_id="O3" value="0.160" lower_limit="0.106" upper_limit="0.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>To account for multiple comparisons, each of the 2 treatment comparisons was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Negative Binomial Regression Model</method>
            <method_desc>Adjusted for region, Baseline age and GdE lesions; included the natural log transformation of available MRI scans as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.370</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.256</ci_lower_limit>
            <ci_upper_limit>0.536</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0182</p_value>
            <p_value_desc>To account for multiple comparisons, each of the 2 treatment comparisons was tested at the alpha = 0.05 level.</p_value_desc>
            <method>Negative binomial regression model</method>
            <method_desc>Adjusted for region, Baseline age and GdE lesions; included the natural log transformation of available MRI scans as an offset term.</method_desc>
            <param_type>Rate Ratio</param_type>
            <param_value>0.662</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.471</ci_lower_limit>
            <ci_upper_limit>0.932</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Disability Progression Confirmed After 3 Months</title>
        <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
        <time_frame>From first dose to the end of the 12-month treatment period</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Disability Progression Confirmed After 3 Months</title>
          <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 3 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
          <population>ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3055</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Based on the Cox proportional hazard model with factors for treatment group, adjusted for region, Baseline age, and Baseline EDSS score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.690</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.340</ci_lower_limit>
            <ci_upper_limit>1.402</ci_upper_limit>
            <estimate_desc>Hazard Ratio (Ozanimod / IFN β-1a)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7163</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Based on the Cox proportional hazard model with factors for treatment group, adjusted for region, Baseline age and Baseline EDSS score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.886</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.460</ci_lower_limit>
            <ci_upper_limit>1.705</ci_upper_limit>
            <estimate_desc>Hazard Ratio (Ozanimod / IFN β-1a)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Disability Progression Confirmed After 6 Months</title>
        <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 6 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
        <time_frame>From first dose to the end of the 12-month treatment period</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Disability Progression Confirmed After 6 Months</title>
          <description>EDSS is used to quantify disability and disability progression over time in MS. Based on a neurological examination, 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel &amp; bladder, cerebral, and other functions) are scored from 0 (no disability) to 5 or 6 (more severe disability). Ambulation is assessed based on distance the patient is able to walk, whether assistance is required or restrictions are present.&#xD;
The EDSS score ranges from 0 (normal) to 10 (death due to MS) in 0.5 unit increments.&#xD;
Disability progression is defined by a sustained worsening in EDSS score of 1.0 point or more confirmed after 6 months. Time to onset of disability progression was calculated from the date of first dose to the date of the first visit at which the 1.0 point increase in EDSS was met using Kaplan-Meier methods. Participants without a sustained disease progression event were censored on the date of their last assessment or last dose of study drug, whichever was later.</description>
          <population>ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not estimable as there were insufficient disability events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6725</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Based on the Cox proportional hazard model with factors for treatment group, adjusted for region, Baseline age and Baseline EDSS score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.238</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.460</ci_lower_limit>
            <ci_upper_limit>3.337</ci_upper_limit>
            <estimate_desc>Hazard Ratio (Ozanimod / IFN β-1a)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3755</p_value>
            <method>Cox proportional hazard model</method>
            <method_desc>Based on the Cox proportional hazard model with factors for treatment group, adjusted for region, Baseline age and Baseline EDSS score</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.535</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.595</ci_lower_limit>
            <ci_upper_limit>3.963</ci_upper_limit>
            <estimate_desc>Hazard Ratio (Ozanimod / IFN β-1a)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Gadolinium Enhancing Lesion-Free at Month 12</title>
        <description>MRI scans were analyzed by blinded centralized reading facility.</description>
        <time_frame>Month 12</time_frame>
        <population>The ITT population; Participants who were missing the Month 12 MRI data were considered non-responders; ie, as not being lesion-free (non-responder imputation).</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Gadolinium Enhancing Lesion-Free at Month 12</title>
          <description>MRI scans were analyzed by blinded centralized reading facility.</description>
          <population>The ITT population; Participants who were missing the Month 12 MRI data were considered non-responders; ie, as not being lesion-free (non-responder imputation).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.17" lower_limit="58.70" upper_limit="67.64"/>
                    <measurement group_id="O2" value="68.29" lower_limit="64.00" upper_limit="72.59"/>
                    <measurement group_id="O3" value="74.05" lower_limit="69.99" upper_limit="78.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on the CMH test stratified by region and EDSS category per Interactive Voice Response System (IVRS)</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>10.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.84</ci_lower_limit>
            <ci_upper_limit>16.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1130</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on the CMH test stratified by region and EDSS category per IVRS.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>5.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>11.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were T2 Lesion-Free at Month 12</title>
        <description>MRI scans were analyzed by blinded centralized reading facility.</description>
        <time_frame>Month 12</time_frame>
        <population>The ITT population; participants who were missing the Month 12 MRI data were considered non-responders, ie, as not being lesion-free.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were T2 Lesion-Free at Month 12</title>
          <description>MRI scans were analyzed by blinded centralized reading facility.</description>
          <population>The ITT population; participants who were missing the Month 12 MRI data were considered non-responders, ie, as not being lesion-free.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.44" lower_limit="19.51" upper_limit="27.36"/>
                    <measurement group_id="O2" value="26.39" lower_limit="22.32" upper_limit="30.45"/>
                    <measurement group_id="O3" value="27.96" lower_limit="23.80" upper_limit="32.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1180</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on the CMH test stratified by region and EDSS Scale category per IVRS.</method_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>4.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>10.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3023</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on the CMH test stratified by region and EDSS Scale category per IVRS.</method_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.70</ci_lower_limit>
            <ci_upper_limit>8.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Normalized Brain Volume at Month 12</title>
        <description>Brain volume (a measure of brain atrophy) was analyzed by MRI.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>The ITT population with available MRI data at Baseline and Month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Normalized Brain Volume at Month 12</title>
          <description>Brain volume (a measure of brain atrophy) was analyzed by MRI.</description>
          <population>The ITT population with available MRI data at Baseline and Month 12</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="334"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" lower_limit="-3.7" upper_limit="1.1"/>
                    <measurement group_id="O2" value="-0.50" lower_limit="-2.7" upper_limit="1.4"/>
                    <measurement group_id="O3" value="-0.39" lower_limit="-2.8" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Due to the non-normal distribution of the data for brain volume loss, the analyses for percent change from baseline in normalized brain volume were compared using rank-ANCOVA, adjusted for region (Eastern Europe vs Rest of World), and EDSS category per IVRS, with the dependent variable as the residual of the rank of brain volume at Baseline regressed on rank of percent change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Rank ANCOVA</method>
            <method_desc>Adjusted for region and EDSS category per IVRS</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to the non-normal distribution of the data for brain volume loss, the analyses for percent change from baseline in normalized brain volume were compared using rank-ANCOVA, adjusted for region (Eastern Europe vs Rest of World), and EDSS category per IVRS, with the dependent variable as the residual of the rank of brain volume at Baseline regressed on rank of percent change.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0615</p_value>
            <method>Rank ANCOVA</method>
            <method_desc>Adjusted for region and EDSS Scale per IVRS</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 12 in Multiple Sclerosis Functional Composite (MSFC) Score Including the Low-Contrast Letter Acuity (LCLA) Test</title>
        <description>The MSFC-LCLA is a battery including the following 4 individual scales:&#xD;
Timed 25-Foot Walk is an ambulation measure of walking 25 feet with time taken recorded in seconds&#xD;
9-Hole Peg Test (9HPT) is a quantitative measure of upper extremity (arm and hand) function&#xD;
Symbol Digit Modalities Test (SDMT) is a measure of executive cognitive function that assesses processing speed, flexibility, and calculation ability&#xD;
Low-Contrast Letter Acuity Test (LCLA) used a standardized set of charts to assess low contrast visual acuity, charts are scored according to the number of letters that are identified correctly&#xD;
Z-scores were calculated for for each component and averaged to create an overall composite score, using the study population as the reference population. A z-score represents the number of standard deviations a patient's test result is higher (z &gt; 0) or lower (z &lt; 0) than the average test result (z = 0) of the reference population. A positive change indicates improvement.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>The ITT population with available Baseline and Month 12 MSFC z-scores.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 12 in Multiple Sclerosis Functional Composite (MSFC) Score Including the Low-Contrast Letter Acuity (LCLA) Test</title>
          <description>The MSFC-LCLA is a battery including the following 4 individual scales:&#xD;
Timed 25-Foot Walk is an ambulation measure of walking 25 feet with time taken recorded in seconds&#xD;
9-Hole Peg Test (9HPT) is a quantitative measure of upper extremity (arm and hand) function&#xD;
Symbol Digit Modalities Test (SDMT) is a measure of executive cognitive function that assesses processing speed, flexibility, and calculation ability&#xD;
Low-Contrast Letter Acuity Test (LCLA) used a standardized set of charts to assess low contrast visual acuity, charts are scored according to the number of letters that are identified correctly&#xD;
Z-scores were calculated for for each component and averaged to create an overall composite score, using the study population as the reference population. A z-score represents the number of standard deviations a patient's test result is higher (z &gt; 0) or lower (z &lt; 0) than the average test result (z = 0) of the reference population. A positive change indicates improvement.</description>
          <population>The ITT population with available Baseline and Month 12 MSFC z-scores.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="450"/>
                <count group_id="O3" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.334"/>
                    <measurement group_id="O2" value="-0.007" spread="0.351"/>
                    <measurement group_id="O3" value="0.003" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1290</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for region, EDSS category per IVRS and the Baseline MSFC score.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.077</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4942</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for region, EDSS category per IVRS and the Baseline MSFC score</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Physical Health Composite Summary and Mental Health Composite Summary Scores</title>
        <description>The MSQOL-54 is a multidimensional health-related QOL measure that combines both generic and MS-specific items into a single instrument. The instrument includes 12 subscales, two summary scores, and two single-item measures.&#xD;
The two summary scores - physical health and mental health - are derived from a weighted combination of scale scores.&#xD;
The physical health composite score includes Physical function, Health perceptions, Energy/fatigue, Role limitations - physical, Pain, Sexual function, Social function, and Health distress.&#xD;
The mental health composite score includes Health distress, Overall quality of life, Emotional well-being, Role limitations - emotional, and Cognitive function.&#xD;
Each composite summary score has a range from 0 to 100 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>ITT population with available Baseline data; missing post-baseline data were imputed using a mixed-effects regression model (random slope and intercept).</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Multiple Sclerosis Quality of Life (MSQOL)-54 Physical Health Composite Summary and Mental Health Composite Summary Scores</title>
          <description>The MSQOL-54 is a multidimensional health-related QOL measure that combines both generic and MS-specific items into a single instrument. The instrument includes 12 subscales, two summary scores, and two single-item measures.&#xD;
The two summary scores - physical health and mental health - are derived from a weighted combination of scale scores.&#xD;
The physical health composite score includes Physical function, Health perceptions, Energy/fatigue, Role limitations - physical, Pain, Sexual function, Social function, and Health distress.&#xD;
The mental health composite score includes Health distress, Overall quality of life, Emotional well-being, Role limitations - emotional, and Cognitive function.&#xD;
Each composite summary score has a range from 0 to 100 where higher scores indicate better quality of life. A positive change from Baseline indicates improvement.</description>
          <population>ITT population with available Baseline data; missing post-baseline data were imputed using a mixed-effects regression model (random slope and intercept).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical health composite summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="448"/>
                    <count group_id="O3" value="443"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="12.578"/>
                    <measurement group_id="O2" value="1.414" spread="12.343"/>
                    <measurement group_id="O3" value="1.925" spread="11.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health composite summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="448"/>
                    <count group_id="O2" value="451"/>
                    <count group_id="O3" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.123" spread="15.240"/>
                    <measurement group_id="O2" value="0.283" spread="15.686"/>
                    <measurement group_id="O3" value="0.260" spread="15.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of Physical Health Composite Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0364</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for region, EDSS category per IVRS, and the Baseline summary score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.642</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.104</ci_lower_limit>
            <ci_upper_limit>3.180</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Physical Health Composite Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1905</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for region, EDSS category per IVRS, and the Baseline summary score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.510</ci_lower_limit>
            <ci_upper_limit>2.559</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis of Mental Health Composite Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7104</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for region, EDSS category per IVRS, and the Baseline summary score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.356</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.523</ci_lower_limit>
            <ci_upper_limit>2.234</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Mental Health Composite Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8587</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for region, EDSS category per IVRS, and the Baseline summary score.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.045</ci_lower_limit>
            <ci_upper_limit>1.705</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events</title>
        <description>An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP). An AE can be any unfavorable or unintended sign, including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. A serious AE (SAE) is any untoward medical occurrence or effect that results in death, is life-threatening, requires hospitalization or prolongation of existing inpatient hospitalization. The investigator assessed the severity of AEs as mild, moderate, or severe.</description>
        <time_frame>From the first dose of study drug until 28 days following the last dose of study drug; mean exposure to study drug was 13.5 months for interferon beta-1a and 13.6 months for each ozanimod group.</time_frame>
        <population>Safety Population consisted of all participants who received at least 1 dose of randomized study medication, analyzed according to the highest dose of ozanimod treatment actually received (up to 1 mg) and not according to the treatment they were randomized to receive, if different.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Ozanimod 0.5 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
          <group group_id="O3">
            <title>Ozanimod 1 mg</title>
            <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events</title>
          <description>An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP). An AE can be any unfavorable or unintended sign, including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. A serious AE (SAE) is any untoward medical occurrence or effect that results in death, is life-threatening, requires hospitalization or prolongation of existing inpatient hospitalization. The investigator assessed the severity of AEs as mild, moderate, or severe.</description>
          <population>Safety Population consisted of all participants who received at least 1 dose of randomized study medication, analyzed according to the highest dose of ozanimod treatment actually received (up to 1 mg) and not according to the treatment they were randomized to receive, if different.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="453"/>
                <count group_id="O3" value="448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336"/>
                    <measurement group_id="O2" value="259"/>
                    <measurement group_id="O3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Moderate or Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Suspected TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Suspected Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Related Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Stopping of Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Study Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Death related to Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug until 28 days following the last dose of study drug; mean exposure to study drug was 13.5 months for interferon beta-1a and 13.6 months for each ozanimod group.</time_frame>
      <desc>The Safety population included all participants who received at least 1 dose of randomized study drug. All participants in the Safety population were analyzed according to the highest dose of ozanimod treatment actually received (up to 1 mg) and not according to the treatment they were randomized to receive, if different.</desc>
      <group_list>
        <group group_id="E1">
          <title>Interferon Beta-1a</title>
          <description>Participants received 30 µg interferon beta-1a by IM injection weekly and matching placebo capsules orally once a day until the last participant had been treated for at least 12 months.</description>
        </group>
        <group group_id="E2">
          <title>Ozanimod 0.5 mg</title>
          <description>Participants received ozanimod 0.5 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
        </group>
        <group group_id="E3">
          <title>Ozanimod 1 mg</title>
          <description>Participants received ozanimod 1 mg orally once a day and a placebo intramuscular injection weekly until the last participant had been treated for at least 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendiceal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Lyme Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Postoperative Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Eye Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fibrin D Dimer Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Benign Ovarian Tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Fibroadenoma Of Breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Invasive Breast Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Testicular Seminoma (Pure) Stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Cervical Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Vascular Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Postmenopausal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="273" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="448"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="453"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="448"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results from a center cannot be submitted for publication before results of multicenter study are published unless it is more than one (1) year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene sixty (60) days prior to submission. Celgene may remove confidential and/or proprietary information before publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne McClain, Senior Manager</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>888-260-1599</phone>
      <email>AMcClain@celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

